Sol Gel Technologies Ltd NASDAQ: SLGL

GoSymbol lookup
Health Care : Pharmaceuticals | Small Cap Value | Based in IsraelCompany profile
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

By the market reaction, not
too much revenue expected!

Finally the approval
The target patient population is big - not sure how much revenue they will generate

https://finance.yahoo.com/news/sol-gel-technologies-announces-fda-131500417.html

Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®

https://finance.yahoo.com/news/sol-gel-technologies-provides-fda-140200390.html

NESS ZIONA, Israel, April 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced an update regarding the U.S. Food and Drug Administration (FDA) approval process for EPSOLAY® (benzoyl peroxide) 5% topical cream for the treatment of Inflammatory lesions of rosacea in adults.

In September of 2020, Sol-Gel was informed by the FDA that the PDUFA goal date for EPSOLAY is April 26, 2021. Subsequently, the COVID-19 pandemic restricted the FDA’s ability to conduct pre-approval inspections. In our most recent written communication with the FDA regarding EPSOLAY, the final content of the labeling was discussed and agreed to. As of today, Sol-Gel has received no notification from the FDA, but did receive email confirmation that that action on the NDA for EPSOLAY could not be taken since a pre-approval inspection of the production site of EPSOLAY still needs to be conducted.

The Company continues to follow-up with the FDA on the scheduling of this inspection.

PDUFA Dates

https://www.benzinga.com/general/biotech/21/04/20779951/the-week-ahead-in-biotech-april-25-may-1-fda-decisions-for-sol-gel-protalix-bio-ardelyx

The Food and Drug Administration is scheduled to announce its verdict on Sol-Gel Technologies Ltd.'s
SLGL 0.21%
new drug application for Epsolay in the treatment of inflammatory lesions of rosacea. The PDUFA date, or the deadline for announcing the decision, is Monday.

The FDA will also rule on Protalix BioTherapeutics, Inc.'s
PLX 4.64%
biologic license application for pegunigalsidase alfa in Fabry disease. The PDUFA date is set for Tuesday.

Wow, a year ago today SLGL
was in the ~$6.40 area.

I thought we discussed BVXV at the time, but i think that with some ~75% positive results it could be huge.

As for RDHL, even greener pastures are to come.

BCLI - I have high hopes.

All in all, results for all 3 will come real soon.

PLX will come into frutation during Jan 2021.

GMDA has topline posotive results but is still stuck in $5 area.

Goodnight from the Holy Land, good fortune and good tidings.

BVXV - did not know about that stock - I made good money in other flu vaccine candidate - NVAX

This looks very promising - missed the big jump. Now the market cap is already in $400 million range so the big jump is gone.

Rdhl is in green for me after a long time

So is BVXV!

As will RDHL be. Are you still in?

I looked at it and missed it. Doing pretty good

One other Israeli stock worth looking into
is BCLI.
Latest PR:

BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS
PR Newswire PR Newswire•July 2, 2020
Topline data expected in 4Q 2020

https://finance.yahoo.com/news/brainstorm-announces-completion-dosing-nurown-104900360.html

BCLI: KOL Event Gives Overview of the use of NurOwn® in Alzheimer’s Disease; Raising Valuation to $25/Share…
Zacks Small Cap Research Zacks Small Cap Research•July 9, 2020

https://finance.yahoo.com/news/bcli-kol-event-gives-overview-131000758.html

I think that the treshhold to obtain FDA approval is quite
low considering the gravity of the ALS disease.

Sol-Gel Technologies Reports First Quarter 2020 Financial Results and Corporate Update

GlobeNewswire GlobeNewswire•May 14, 2020

New Drug Applications for Epsolay® and Twyneo® remain on track for the second quarter and second half 2020, respectively
Completed a $23 million underwritten public offering in February with an additional $5 million investment from Sol-Gel’s controlling shareholder in April, providing cash runway into mid-2021 and funds pre-commercialization efforts for Epsolay and Twyneo
Top-line generic product revenue of $3.4 million in first quarter 2020

NESS ZIONA, Israel, May 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the first quarter ended March 31, 2020 and provided an update on its clinical development programs.

“In the first quarter of 2020, we strengthened our balance sheet through a $23 million underwritten public offering in February and a subsequent $5 million private placement that closed just after the end of the first quarter. This capital from new and existing shareholders, including our controlling shareholder, M. Arkin Dermatology Ltd., extends our cash runway to mid-2021, and funds our pre-commercialization efforts for Epsolay and Twyneo,” commented Dr. Alon Seri-Levy, Chief Executive Officer of Sol-Gel. “We remain on track to file our New Drug Application (NDA) for Epsolay with the FDA in the second quarter of this year and our NDA for Twyneo in the second half this year, both exciting milestones for the company.”

“I also want to acknowledge the efforts of our employees and the whole healthcare system in working to keep our community safe during the ongoing COVID-19 pandemic,” continued Dr. Seri-Levy. “At Sol-Gel, we have been fortunate to have seen only minimal impact to our operations to date, largely due to the advanced clinical status of our two lead programs, Epsolay and Twyneo.”

Corporate Highlights and Recent Developments

Strengthened balance sheet with $28.0 million in gross proceeds from the February underwritten public offering of $23.0 million and from the $5.0 million that Sol-Gel’s controlling shareholder, M. Arkin Dermatology Ltd., invested in April. Despite market conditions, the April purchase of ordinary shares and warrants was at the same terms as the February underwritten public offering, $11.00 per ordinary share and an accompanying warrant to purchase 0.80 of an ordinary share. The warrants have an initial exercise price of $14.00 per share, subject to certain adjustments, and will expire on February 19, 2023.

In the first quarter of 2020, Sol-Gel generated revenue of $3.4 million from its collaboration agreement with Perrigo.

In response to COVID-19, Sol-Gel immediately implemented policies and procedures to protect the health, safety and welfare of employees and their families and to help mitigate the spread of the coronavirus including mandatory work-from-home and frequent on-site sterilization.
Clinical Program Updates

Sol-Gel expects to file an NDA for Epsolay (encapsulated benzoyl peroxide, 5%, cream) in the second quarter of 2020. If approved, Epsolay has the potential to be the first FDA-approved single-agent BPO prescription drug product and to redefine the standard of care for the treatment of inflammatory lesions associated with rosacea.

Sol-Gel expects to file an NDA for Twyneo (encapsulated benzoyl peroxide, 3%, and encapsulated tretinoin, 0.1%, cream) in the second half of 2020. If approved, Twyneo has the potential to become a preferred treatment for acne.

In January, Sol-Gel announced positive topline results from an open-label long-term safety study of Epsolay. Of the 209 patients (57.6%) that completed 52 weeks of treatment with Epsolay, 153 (73.2%) reached “clear” or “almost clear”, 46 (22%) reached “mild” rosacea, only 10 (4.8%) had “moderate” rosacea, and none had “severe” rosacea on a Global Assessment (IGA) 5-point scale. Additionally, at the end of the study, more than 90% of these patients had “none” or “mild” cutaneous signs or symptoms (burning or stinging, itching, dryness and scaling) and no “severe” scores were recorded.

A proof of concept clinical study of SGT-210, erlotinib gel, a topical epidermal growth factor receptor inhibitor, for the potential treatment of punctuate palmoplantar keratoderma type 1 initiated in January 2020. This clinical study was recently expanded to include other types of palmoplantar keratoderma. Patient enrollment is expected to be renewed subject to Israel Ministry of Health guidelines for COVID-19. Data is expected in 2021.

In early 2020, Sol-Gel added to its pre-clinical pipeline tapinarof, an aryl hydrocarbon receptor agonist, and roflumilast, a PDE4 inhibitor, each to be developed for potential treatment of psoriasis, as mono or combination therapies and other dermatological indications. Sol-Gel continues to work to advance these assets into the clinic.
Financial Results for the Three Months ended March 31, 2020

Revenue in the first quarter 2020 was $3.5 million. The revenue was mainly due to sales of a generic product from the collaboration arrangement with Perrigo. The decrease in revenue from the previous quarter follows from continued generic competition.

Research and development expenses were $7.9 million in the first quarter of 2020 compared to $10.8 million during the same period in 2019. The decrease of $2.9 million was mainly attributed to a decrease of $2.6 million in clinical trial expenses, mainly related to clinical trials of Epsolay and a decrease of $0.5 million in manufacturing expenses of Epsolay and Twyneo, partially offset by an increase of $0.2 million in regulatory expenses, mainly related to preparing for the NDA submissions for Epsolay and Twyneo.

General and administrative expenses were $2.8 million in the first quarter of 2020 compared to $1.7 million during the same period in 2019. The increase of $1.1 million was mainly attributed to an increase of $1.0 million in commercialization expenses and an increase of $0.1 million in other expenses.

Sol-Gel reported a loss of $7.1 million for the first quarter of 2020 compared to loss of $5.7 million for the same period in 2019.

As of March 31, 2020, Sol-Gel had $20.4 million in cash, cash equivalents and deposits and $45.8 million in marketable securities for a total balance of $66.2 million, excluding the additional $5.0 million investment by Sol-Gel’s controlling shareholder which closed in April. Based on current assumptions, Sol-Gel expects its existing cash resources will enable funding of operational and capital expenditure requirements into mid-2021. As previously disclosed, Sol-Gel does not plan to raise additional dilutive capital to fund pre-commercialization activities for Epsolay and Twyneo.

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctate palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.

https://finance.yahoo.com/news/sol-gel-technologies-reports-first-110510585.html

Sol-Gel Technologies to Report First Quarter 2020 Financial Results and Company Updates on May 14, 2020
May 07 2020 - 04:05PM
GlobeNewswire Inc.

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report its first quarter 2020 financial results and operational highlights on Thursday, May 14, 2020 at 7:05 AM ET.

Thanks for highlighting those 2 important points my friend!!!

Aquestive Therapeutics Inc. (AQST)

Next up is biotech Aquestive Therapeutics, which uses innovative drug delivery technology to redesign important medicines. With not one but two upcoming PDUFA dates, it’s not surprising that members of the Street think its $3.55 share price represents the ideal entry point.
Weighing in for H.C. Wainwright, five-star analyst Raghuram Selvaraju believes that the most valuable piece of the puzzle is its anti-seizure candidate, Libervant, the PDUFA date for which is slated for September 27. “We estimate that Libervant could generate U.S. sales approaching $300 million by 2030. Libervant has been accorded Orphan Drug status, which would confer seven-year market exclusivity upon the product if approved,” he explained.
Regarding Libervant’s launch, Selvaraju argues the fact that Sympazan (clobazam), an oral film for Lennox-Gastaut syndrome (LGS)-associated seizures, was launched prior to Libervant provides Aquestive with the opportunity to set up its commercial infrastructure.
It should also be noted that Selvaraju sees the recent share price weakness as not fully reflecting AQST’s value, with it boasting several other promising candidates in its pipeline. “In our view, the recent coronavirus crisis-driven market disruption has resulted in massively overdone attrition in Aquestive's share price. The company currently trades at a sub-$60 million market cap, which we believe does not reflect even the value of its manufacturing and licensing-related revenue, let alone revenue generated from its proprietary products,” he commented.
One of these candidates is APL-130277, which could be approved on May 21. On top of this, AQST-108 could enter clinical testing this year, and with the annual U.S. epinephrine product market potentially totaling $5.2 billion by 2026, according to Coherent Market Insights, Selvaraju highlights the large opportunity for the biotech.
As a result, Selvaraju reiterated a Buy rating and $13 price target. Should this target be met, a twelve-month gain of 266% could be in the cards. (To watch Selvaraju’s track record, click here)
Looking at the consensus breakdown, other analysts also see big things in store. With 100% Street support, the message is clear: AQST is a Strong Buy. The $17.33 average price target is more aggressive than Selvaraju’s and suggests 388% upside potential. (See Aquestive stock analysis on TipRanks)

https://finance.yahoo.com/news/3-biotech-stocks-under-4-115140896.html

Good luck Dorseye

Thanks, they are killing me!

Man I hate these POP UP ADDS just getting into reading your post and here comesb E*TRADE pop/up which took a few minutes to get back to your post. Anybody else experiencing this problem?

3 Top Biotech Stocks with FDA Approvals on the Horizon

https://www.nasdaq.com/articles/3-top-biotech-stocks-with-fda-approvals-on-the-horizon-2020-04-19

Evofem Biosciences Inc. (EVFM)
Epizyme (EPZM)
Heron Therapeutics (HRTX)

Note: I have none of above, but will keep track

Since i am staying at home, i have lots
of time doing research.

One of my largest holdings is GMDA

Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of Omidubicel
January 2, 2020 at 8:01 AM EST
PDF Version
– Topline data expected in first half of 2020 –

BOSTON--(BUSINESS WIRE)--Jan. 2, 2020-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, announced that in December the company completed patient enrollment in its Phase 3 study of the company’s lead clinical program, omidubicel, an investigational advanced cell therapy being evaluated as a potential life-saving treatment option for patients with high-risk hematologic malignancies who are in need of a bone marrow transplant. Topline data from the study are expected in the first half of 2020.

“Completing patient recruitment for the Phase 3 study of omidubicel is a very significant milestone for our company,” stated Julian Adams, Ph.D., chief executive officer of Gamida Cell. “Positive data would enable us to file our first biologics license application in the second half of 2020 and would represent an important step toward becoming a fully integrated company that can bring breakthrough medicines to patients.”

It is estimated that more than 40 percent of eligible patients in the U.S. do not receive a bone marrow transplant for various reasons, including inability to find a matched donor, despite its curative potential.1 Even for patients who do receive a transplant, the procedure is not always effective and can lead to serious complications that dramatically affect quality of life.2 Omidubicel is intended to address the current limitations of bone marrow transplant by providing a therapeutic dose of stem cells while preserving the cells’ functional therapeutic characteristics.

“For many patients with high-risk hematologic malignancies who are in remission, their only hope of remaining cancer-free is to undergo a bone marrow transplant. While the scientific community has made strides in improving bone marrow transplant, there is still a significant need to make this potentially curative treatment option available to more patients,” said Ronit Simantov, M.D., chief medical officer of Gamida Cell. “We truly appreciate the participation of patients and the support we have received from investigators who believe this clinical trial is critical for moving the field forward.”

The international, multi-center, randomized Phase 3 study (NCT02730299) is designed to evaluate the safety and efficacy of omidubicel compared to standard umbilical cord blood in patients with high-risk hematologic malignancies who need a bone marrow transplant and do not have an available matched donor. The primary endpoint is time to neutrophil engraftment. The study includes approximately 120 patients aged 12-65 with acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome or lymphoma. The study is taking place at over 50 clinical centers in the U.S., Latin America, Europe and Asia.

About Omidubicel
Omidubicel (formerly known as NiCord®), the company’s lead clinical program, is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has also received Orphan Drug Designation in the U.S. and EU. In a Phase 1/2 clinical study, omidubicel demonstrated rapid and durable time to engraftment and was generally well tolerated.3 A Phase 3 study evaluating omidubicel in patients with leukemia and lymphoma is ongoing in the U.S., Latin America, Europe and Asia.4 Omidubicel is also being evaluated in a Phase 1/2 clinical study in patients with severe aplastic anemia.5 The aplastic anemia investigational new drug application is currently filed with the FDA under the brand name CordIn®, which is the same investigational development candidate as omidubicel. For more information on clinical trials of omidubicel, please visit www.clinicaltrials.gov.

Omidubicel is an investigational therapy, and its safety and efficacy have not been evaluated by the U.S. Food and Drug Administration or any other health authority.

About Gamida Cell
Gamida Cell is an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit
https://www.gamida-cell.com/

Mind you, i am not recommending to follow my footsteps. i
have made many investing mistakes, made a fortune and
encountered HUGE losses as well.

Finally results for both BVXV and GMDA are not too far away!

I get it, there is a slight mixup:

from https://www.prnewswire.com/il/news-releases/preliminary-data-from-nihniaid-sponsored-phase-2-clinical-trial-of-biondvaxs-m-001-universal-influenza-vaccine-candidate-validates-results-of-previous-clinical-trials-300999644.html


there are 2 subjects:

1/ preliminary data from the Phase 2 clinical trial of BiondVax's M-001 universal influenza vaccine candidate have been published. The trial was supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The primary objectives of the trial were to assess safety and T-cell responses to M-001. The data, which are consistent with results of previous clinical trials of M-001, indicate that both primary objectives were achieved. Analysis of the data is ongoing, and the clinical study report (CSR) is expected in Q2 2020.


2/In parallel, BiondVax's pivotal, clinical efficacy, Phase 3 trial in Europe, involving 12,463 older adults, is ongoing. Results of that trial are expected by the end of 2020.

Good listing - you did not list RDHL - then we share 3 of them.

Israel comes with great technology and success but stock market success is different story.

I am waiting for RDHL to come out of Red to get at least one success.

Bvxv - here is latest from Mar 19th report. So the results are year end and not Q2

“ As long as the pandemic situation does not further significantly deteriorate, our CRO and statistician currently expect us to reach the targeted number of swab samples. We will continue to take all appropriate and feasible steps to enable us to publish results by the end of this year."”

What do you guys think?
(copied from the net)

I'm not at all a conspiratorialist, but SOMETHING IS FISHY IN CHINA

*SOMETHING IS FISHY!!*??

Wuhan to Shanghai = 839 km
Wuhan to Beijing = 1,152 km
Wuhan to Milan = 8,684 km
Wuhan to NY = 12,033 km

The Coronavirus started in Wuhan yet there is no effect of Coronavirus in nearby Beijing or Shanghai but many deaths in Italy, Iran, European countries and USA.

All business areas of China are now safe.

*Something is fishy.*

America is not just blaming China without a reason.

Even today, India is locked down but all the cities of China are open. China has also announced the opening of Wuhan from April 08. Not a single leader in China has tested positive for the deadly Coronavirus.

*Something is fishy.*

The virus has ruined many economies around the world. Many have had to close their borders in an attempt to contain and control the spread of the Coronavirus. Thousands have lost their lives, millions have now got this disease, countless people have been locked in their homes and many countries have placed their citizens on lock down.

*Something is fishy.*

The Coronavirus orginated from the city of Wuhan in China and has now reached every corner of the world, but the virus did not reach China's capital Beijing and China's Economic Capital Shanghai, located in close proximity to Wuhan itself.

*Something is fishy*

Today Paris is closed, New York is closed, Berlin is closed, Delhi is closed, Mumbai is closed, Tokyo is closed, the world's major economic and political centers are closed, but Beijing and Shanghai are open. No Coronavirus effect is seen in either cities. There were only a few cases but the virus had no real effect on Beijing and Shanghai.

*Something is fishy.*

Beijing is the city where all the leaders of China live, including their military leaders. There is no lock down in Beijing.

*Something is fishy*


Shanghai is the city that runs China's economy. It is the economic capital of China, where all the rich people of China live and run major industries. There is no lock down here, there is no effect of the Coronavirus there.

*Something is fishy*


Beijing and Shanghai are the areas adjoining Wuhan. The virus from Wuhan reached every corner of the world, but the virus did not affect Beijing and Shanghai.

*Something is fishy*


Another big thing is, that the worldwide share market has fallen by almost half. In India also the Nifty has gone from 12 thousand to 7 thousand, but the share market of China was at 3000 and just merely dropped to 2700.

*Something is fishy*


This leaves one to speculate that the Coronavirus is a bio-chemical weapon of China, which China used to carry out destruction in the world in order to gain economic supremacy.

China has now put this virus under control, maybe they also have the antidote/ vaccine that they are not sharing with the world ever or will do when it is in their best interest to do so.

*Something is fishy*


Hollywood stars, Australia's Home Minister, Britain's Prime Minister and Health Minister, Spain's Prime Minister's wife, Canada's Prime Minister's wife, and Britain's Prince Charles, among others, have contracted the Coronavirus, but NOT A SINGLE POLITICAL LEADER IN CHINA, NOT A SINGLE MILITARY COMMANDER in China have tested positive for Coronavirus*SOMETHING IS FISHY!!!

Copied from the net

Re: BVXV

BLRX soaked quite a lot of $$$
from my bank account. I left some
shares just for academic interest.

KTOV was one on my largest failures,
although i am in the deep red i still
keep it, for offsetting some gains in
others some time.

PARS was my largest loss by far, a
few years ago

TEVA was my largest gain ever.

BVXV has imo the largest potential if
of course they achieve FDA approval.
That said, there have been great Israeli
bio company success stories, and some
loud shattering collapses as well.

Take into consideration that Israel is #1
in foreign companies listed in the US.

Good Luck

Good find - it is an Israeli co and I have not made any profit in any Israeli co - they start promising and end in dumpsters - lost big in BLRX-KTOV-RDHL. At least RDHL is live

This one has potential - good news is trial is over and results will by end of the year.
If it drops to $6 range I might consider buying

“Topline results will be available before the end of 2020, at which time the company will have data on 12,463 individuals to determine if M-001 is effective in reducing influenza illness against all naturally encountered influenza strains for one influenza season. We anticipate that additional trials aimed at extending the indication to more than one year are likely once M-001 reaches the market.”

Thanks, adding it to my watch list!

One other company i recommend looking
into is BVXV.

A short description of the company:

About BiondVax

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is Phase 3 clinical phase bio pharmaceutical company developing the M-001 Universal Flu Vaccine. M-001 is currently undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. Results of the clinical trial are expected by the end of 2020.

M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 7 completed clinical trials the vaccine was shown to be safe, well tolerated and immunologic to a broad range of flu strains.

More at http://www.biondvax.com/

Disclosure: I own some 270 shares.

Since you are into bios, i think that this one has great
potential. Can you imagine the potential of a universal flu vaccine?

Influenza is not a hot subject nowadays, Corona took all
limelight, but its day will come - hopefully

Thanks for starting this board my friend!

Same here guys, I get sick every time I look at REGN, over 500 bucks a share I had 10k and sold@17... thought I thought I did something????

Thanks for that info on the drugs!

Just starting my research, company certainly looks strong financially........
Balance Sheet
Total Cash (mrq) ...........:.......50.38M
Total Cash Per Share (mrq) .....2.24
Total Debt (mrq) .....................2.04M
Total Debt/Equity (mrq) .............3.90
Current Ratio (mrq) .....................8.58
Book Value Per Share (mrq) .....2.57

Not a bad 1st day after the board is open

LOL, I hope i don't jinx this one!



Anyway, i am in since yesterday @$7.37,
I have not done serious DD, but i have
patience.
I lost a lot in bios, but made some
fortunes on some as well, all in all
i never invest more than i can afford
to lose.

Good Luck

Good investor presentation


https://ir.sol-gel.com/static-files/02fa6fd4-2aef-40c4-8f48-ec8628aea705

Thanks Midas for starting the mb here.

As I mention I like the co for few reasons

1. It has 2 NDAs coming in next 6 months
2. Many small companies are getting hit by clinical trial delays. This co is out of it.
3. The clinical trial delays are going to be long, hospitals will take many months to come back to normal and start the trials back, in some cases enroll more patients as some of the patients have lost few follow up visits.
Based on this I am focused on small pharma or biotechs who have finished their trials or submitted NDAs
4. The co has money to sustain
5. The 2 drugs of approved will become new SOC. Both indications are facial ones so it has ready market and will have pricing power.

The key is - investor has to hold for at least 1 year for first approval and another 6 months for next approval. During this period one can get this stock at lower price as well.

At $168 million market cap it has at least 3 bagger potential in mind from current price in 2 years.


“Our goals for 2020 are no less ambitious as we plan to file two New Drug Applications (NDA) in the U.S. – Epsolay in the second quarter of 2020 and Twyneo in the second half. In parallel, we are planning commercialization efforts and advancing development of our proprietary pipeline, while benefiting from our strong generic collaborations.” “
In terms of COVID-19 impact,” continued Dr. Seri-Levy, “given that Sol-Gel has completed the clinical programs required to support the NDAs for both Epsolay and Twyneo, and given that Sol-Gel recently strengthened its balance sheet, we remain on track to file both NDAs in the previously communicated timelines.”

Sol-Gel Technologies Reports Full Year 2019 Financial Results and Corporate Update
GlobeNewswire GlobeNewswire•March 24, 2020

Top-line generic product revenue of $22.8 million in fiscal 2019
New Drug Applications for Epsolay® and Twyneo® remain on track for the second quarter and second half 2020, respectively

NESS ZIONA, Israel, March 24, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today provided a corporate update and reported financial results for the full year ended December 31, 2019.
“I am very proud of the major milestones that were accomplished by Sol-Gel in 2019. We announced positive top-line data from not one, but two clinical dermatological programs, Epsolay® in papulopustular rosacea and Twyneo® in acne vulgaris,” commented Dr. Alon Seri-Levy, Chief Executive Officer of Sol-Gel. “Our goals for 2020 are no less ambitious as we plan to file two New Drug Applications (NDA) in the U.S. – Epsolay in the second quarter of 2020 and Twyneo in the second half. In parallel, we are planning commercialization efforts and advancing development of our proprietary pipeline, while benefiting from our strong generic collaborations.”
“In terms of COVID-19 impact,” continued Dr. Seri-Levy, “given that Sol-Gel has completed the clinical programs required to support the NDAs for both Epsolay and Twyneo, and given that Sol-Gel recently strengthened its balance sheet, we remain on track to file both NDAs in the previously communicated timelines. This is of course, a dynamic situation which we will be monitoring closely.”
Corporate Highlights and Recent Developments
Strengthened balance sheet with underwritten public offerings of $23 million of gross proceeds in February 2020 and $11.5 million of gross proceeds in August 2019; Sol-Gel’s controlling shareholder, M. Arkin Dermatology Ltd., has agreed to invest an additional $5 million on the same terms as the February 2020 public offering, subject to shareholder approval.
In the fiscal year 2019, Sol-Gel generated revenue of $22.8 million from its collaboration agreement with Perrigo.
In September 2019, Sol-Gel was granted a patent from the United States Patent and Trademark Office for a patent covering Twyneo for the treatment of acne vulgaris. The newly granted patent will extend protection to July 2038, which Sol-Gel believes will prevent the launch of AB-rated generics of Twyneo during the life of the patent
Clinical Program Updates
Story continues
In December 2019, Sol-Gel announced that Twyneo met all co-primary endpoints in the treatment of patients with acne vulgaris. Sol-Gel expects to file a NDA in the second half of 2020. If approved, Twyneo has the potential to become a preferred treatment for acne.
In July 2019, Sol-Gel announced that Epsolay met all primary and secondary endpoints in both Phase 3 trials in papulopustular rosacea. Epsolay also demonstrated a rapid onset of action with statistically significant improvement seen as early as Week 2 compared with vehicle. Sol-Gel expects to file a NDA in the first half of 2020. If approved, Epsolay has the potential to be the first FDA-approved single-agent BPO prescription drug product and to redefine the standard of care for the treatment of inflammatory lesions associated with subtype II rosacea.
A proof of concept clinical study of SGT-210, erlotinib gel, a topical epidermal growth factor receptor inhibitor, for the potential treatment of punctuate palmoplantar keratoderma type 1 initiated in January 2020. Data is expected in the first half of 2021.
In early 2020, Sol-Gel added to its pre-clinical pipeline tapinarof, an aryl hydrocarbon receptor agonist, and roflumilast, a PDE4 inhibitor, each to be developed for potential treatment of psoriasis, as mono or combination therapies and other dermatological indications.

https://finance.yahoo.com/news/sol-gel-technologies-reports-full-200510067.html